Dual  ||| S:0 E:5 ||| JJ
restoring  ||| S:5 E:15 ||| JJ
effects  ||| S:15 E:23 ||| NNS
of  ||| S:23 E:26 ||| IN
gastrodin  ||| S:26 E:36 ||| NN
on  ||| S:36 E:39 ||| IN
dopamine  ||| S:39 E:48 ||| NN
in  ||| S:48 E:51 ||| IN
rat  ||| S:51 E:55 ||| JJ
models  ||| S:55 E:62 ||| NNS
of  ||| S:62 E:65 ||| IN
Tourette ||| S:65 E:73 ||| NNP
's  ||| S:73 E:76 ||| POS
syndrome  ||| S:76 E:85 ||| NN
Tourette ||| S:85 E:93 ||| NNP
's  ||| S:93 E:96 ||| POS
syndrome  ||| S:96 E:105 ||| NN
( ||| S:105 E:106 ||| -LRB-
TS ||| S:106 E:108 ||| NNP
)  ||| S:108 E:110 ||| -RRB-
occurs  ||| S:110 E:117 ||| VBZ
commonly  ||| S:117 E:126 ||| RB
in  ||| S:126 E:129 ||| IN
children ||| S:129 E:137 ||| NNS
,  ||| S:137 E:139 ||| ,
and  ||| S:139 E:143 ||| CC
dysfunction  ||| S:143 E:155 ||| NN
of  ||| S:155 E:158 ||| IN
dopaminergic  ||| S:158 E:171 ||| JJ
system  ||| S:171 E:178 ||| NN
has  ||| S:178 E:182 ||| VBZ
long  ||| S:182 E:187 ||| RB
been  ||| S:187 E:192 ||| VBN
postulated  ||| S:192 E:203 ||| VBN
to  ||| S:203 E:206 ||| TO
underlie  ||| S:206 E:215 ||| VB
the  ||| S:215 E:219 ||| DT
disorder ||| S:219 E:227 ||| NN
.  ||| S:227 E:229 ||| .
Here ||| S:229 E:233 ||| RB
,  ||| S:233 E:235 ||| ,
we  ||| S:235 E:238 ||| PRP
used  ||| S:238 E:243 ||| VBD
two  ||| S:243 E:247 ||| CD
TS  ||| S:247 E:250 ||| JJ
rat  ||| S:250 E:254 ||| NN
models  ||| S:254 E:261 ||| NNS
induced  ||| S:261 E:269 ||| VBN
by  ||| S:269 E:272 ||| IN
3,3 ||| S:272 E:275 ||| NNP
' ||| S:275 E:276 ||| POS
-iminodipropionitrile  ||| S:276 E:298 ||| JJ
( ||| S:298 E:299 ||| -LRB-
IDPN ||| S:299 E:303 ||| NNP
)  ||| S:303 E:305 ||| -RRB-
and  ||| S:305 E:309 ||| CC
Apomorphine  ||| S:309 E:321 ||| NNP
( ||| S:321 E:322 ||| -LRB-
Apo ||| S:322 E:325 ||| NNP
)  ||| S:325 E:327 ||| -RRB-
to  ||| S:327 E:330 ||| TO
assess  ||| S:330 E:337 ||| VB
an  ||| S:337 E:340 ||| DT
unique  ||| S:340 E:347 ||| JJ
dopamine  ||| S:347 E:356 ||| NNS
( ||| S:356 E:357 ||| -LRB-
DA ||| S:357 E:359 ||| NNP
)  ||| S:359 E:361 ||| -RRB-
modulating  ||| S:361 E:372 ||| JJ
property  ||| S:372 E:381 ||| NN
of  ||| S:381 E:384 ||| IN
gastrodin  ||| S:384 E:394 ||| NNS
( ||| S:394 E:395 ||| -LRB-
GAS ||| S:395 E:398 ||| NNP
) ||| S:398 E:399 ||| -RRB-
,  ||| S:399 E:401 ||| ,
the  ||| S:401 E:405 ||| DT
main  ||| S:405 E:410 ||| JJ
bioactive  ||| S:410 E:420 ||| JJ
component  ||| S:420 E:430 ||| NN
isolated  ||| S:430 E:439 ||| VBN
from  ||| S:439 E:444 ||| IN
Gastrodia  ||| S:444 E:454 ||| NNP
elata  ||| S:454 E:460 ||| VBD
Blume ||| S:460 E:465 ||| NNP
,  ||| S:465 E:467 ||| ,
which  ||| S:467 E:473 ||| WDT
has  ||| S:473 E:477 ||| VBZ
been  ||| S:477 E:482 ||| VBN
widely  ||| S:482 E:489 ||| RB
used  ||| S:489 E:494 ||| VBN
for  ||| S:494 E:498 ||| IN
treating  ||| S:498 E:507 ||| VBG
various  ||| S:507 E:515 ||| JJ
neurological  ||| S:515 E:528 ||| JJ
disorders ||| S:528 E:537 ||| NNS
.  ||| S:537 E:539 ||| .
By  ||| S:539 E:542 ||| IN
using  ||| S:542 E:548 ||| VBG
high-performance  ||| S:548 E:565 ||| JJ
liquid  ||| S:565 E:572 ||| JJ
chromatography  ||| S:572 E:587 ||| NNS
( ||| S:587 E:588 ||| -LRB-
HPLC ||| S:588 E:592 ||| NNP
) ||| S:592 E:593 ||| -RRB-
,  ||| S:593 E:595 ||| ,
the  ||| S:595 E:599 ||| DT
dual  ||| S:599 E:604 ||| JJ
restoring  ||| S:604 E:614 ||| JJ
effects  ||| S:614 E:622 ||| NNS
of  ||| S:622 E:625 ||| IN
gastrodin ||| S:625 E:634 ||| NN
,  ||| S:634 E:636 ||| ,
at  ||| S:636 E:639 ||| IN
least  ||| S:639 E:645 ||| JJS
partially ||| S:645 E:654 ||| RB
,  ||| S:654 E:656 ||| ,
has  ||| S:656 E:660 ||| VBZ
been  ||| S:660 E:665 ||| VBN
observed ||| S:665 E:673 ||| VBN
:  ||| S:673 E:675 ||| :
on  ||| S:675 E:678 ||| IN
the  ||| S:678 E:682 ||| DT
one  ||| S:682 E:686 ||| CD
hand ||| S:686 E:690 ||| NN
,  ||| S:690 E:692 ||| ,
gastrodin  ||| S:692 E:702 ||| VBD
increased  ||| S:702 E:712 ||| VBN
the  ||| S:712 E:716 ||| DT
down-regulated  ||| S:716 E:731 ||| JJ
striatal  ||| S:731 E:740 ||| JJ
DA  ||| S:740 E:743 ||| NNP
content  ||| S:743 E:751 ||| NN
in  ||| S:751 E:754 ||| IN
IDPN-induced  ||| S:754 E:767 ||| JJ
rats ||| S:767 E:771 ||| NNS
;  ||| S:771 E:773 ||| :
on  ||| S:773 E:776 ||| IN
the  ||| S:776 E:780 ||| DT
other  ||| S:780 E:786 ||| JJ
hand ||| S:786 E:790 ||| NN
,  ||| S:790 E:792 ||| ,
gastrodin  ||| S:792 E:802 ||| NN
decreased  ||| S:802 E:812 ||| VBD
the  ||| S:812 E:816 ||| DT
up-regulated  ||| S:816 E:829 ||| JJ
striatal  ||| S:829 E:838 ||| JJ
DA  ||| S:838 E:841 ||| NNP
content  ||| S:841 E:849 ||| NN
in  ||| S:849 E:852 ||| IN
Apo-induced  ||| S:852 E:864 ||| JJ
rats ||| S:864 E:868 ||| NNS
.  ||| S:868 E:870 ||| .
Taken  ||| S:870 E:876 ||| VBN
together ||| S:876 E:884 ||| RB
,  ||| S:884 E:886 ||| ,
our  ||| S:886 E:890 ||| PRP$
data  ||| S:890 E:895 ||| NNS
corroborated  ||| S:895 E:908 ||| VBP
that  ||| S:908 E:913 ||| DT
gastrodin  ||| S:913 E:923 ||| NN
could  ||| S:923 E:929 ||| MD
restore  ||| S:929 E:937 ||| VB
the  ||| S:937 E:941 ||| DT
abnormal  ||| S:941 E:950 ||| FW
striatal  ||| S:950 E:959 ||| FW
DA  ||| S:959 E:962 ||| FW
dually ||| S:962 E:968 ||| FW
,  ||| S:968 E:970 ||| ,
and  ||| S:970 E:974 ||| CC
this  ||| S:974 E:979 ||| DT
therapeutic  ||| S:979 E:991 ||| JJ
potential  ||| S:991 E:1001 ||| NN
might  ||| S:1001 E:1007 ||| MD
be  ||| S:1007 E:1010 ||| VB
meaningful  ||| S:1010 E:1021 ||| JJ
for  ||| S:1021 E:1025 ||| IN
the  ||| S:1025 E:1029 ||| DT
anti-tic  ||| S:1029 E:1038 ||| JJ
treatment ||| S:1038 E:1047 ||| NN
.  ||| S:1047 E:1049 ||| .
